Artiva Biotherapeutics, Inc.
ARTV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARTV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell therapies, with its lead candidate AlloNK in clinical trials and other programs in preclinical stages.
Key risk: Dependence on AlloNK
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials for Artiva Biotherapeutics, Inc..
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell therapies, with its lead candidate AlloNK in clinical trials and other programs in preclinical stages.
- Lead product candidate AlloNK (AB-101) is in clinical development; other internally developed candidates are preclinical or discovery stage [sec_mda · as of 2026-03-10].
- Cash and equivalents of $301.9M as of 2026-06-30, with a net loss of $25.0M for the period [sec].
- Shareholders' equity of $149.0M as of 2026-06-30 [sec].
- The company has not yet demonstrated ability to complete large-scale pivotal trials, obtain marketing approval, or commercialize a product [sec_mda · as of 2026-03-10].
What works
- Cash position of $301.9M as of 2026-06-30 provides a substantial runway to fund operations and clinical development [sec].
- Lead candidate AlloNK is already in clinical trials, indicating progress toward potential regulatory milestones [sec_mda · as of 2026-03-10].
- The company has a strategic collaboration with Merck, which provided a $30.0M upfront payment and additional research service payments [sec_mda · as of 2024-08-29].
What to weigh
- Artiva has a history of losses, with an accumulated deficit of $213.1M as of June 30, 2024, and expects to incur significant losses for the foreseeable future [sec_mda · as of 2024-08-29].
- The company is substantially dependent on the success of AlloNK, with all other internally developed candidates in preclinical or discovery stages [sec_mda · as of 2026-03-10].
- Artiva has not yet demonstrated the ability to complete large-scale pivotal trials, obtain marketing approval, or commercialize a product [sec_mda · as of 2026-03-10].
- The company will require substantial additional funding to complete development and commercialization of its product candidates [sec_mda · as of 2026-03-10].
From the filings
Quoted directly from source documents.
Artiva is substantially dependent on AlloNK, which is in clinical development.
“We are substantially dependent on the success of our lead product candidate, AlloNK, which is in clinical development.”
SEC MD&A · March 10, 2026
The company has not yet demonstrated ability to complete pivotal trials or commercialize.
“We have not yet demonstrated an ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approval, manufacture product at a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization.”
SEC MD&A · March 10, 2026
The company had an accumulated deficit of $213.1M as of June 30, 2024.
“As of June 30, 2024, we had cash, cash equivalents and short-term investments of $46.6 million and an accumulated deficit of $213.1 million.”
SEC MD&A · August 29, 2024
Risks & what to watch (4)›
Key risks
- Dependence on AlloNK — Artiva is substantially dependent on the success of its lead candidate AlloNK; other candidates are preclinical [sec_mda · as of 2026-03-10].
- History of losses — Accumulated deficit of $213.1M as of June 30, 2024; expects significant losses for the foreseeable future [sec_mda · as of 2024-08-29].
- Need for additional funding — Will require substantial additional capital to complete development and commercialization [sec_mda · as of 2026-03-10].
- No commercial experience — Has not demonstrated ability to complete pivotal trials, obtain approval, or commercialize a product [sec_mda · as of 2026-03-10].
What to watch
- Clinical trial results for AlloNK, including initial data from autoimmune indications expected in first half of 2025 [sec · filed 2024-06-28].
- Timing of planned Investigational New Drug (IND) submissions to the FDA for AlloNK and other candidates [sec · filed 2026-08-06].
- Future capital raises or strategic collaborations to fund ongoing operations and development [sec_mda · as of 2026-03-10].
- Progress of preclinical candidates (AB-201, AB-205) toward clinical development [sec_mda · as of 2026-03-10].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Artiva Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Artiva Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
51.3 months
D/E 0.06 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
21 buys · 6 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$77.9M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 9,853,302 | $63.5M |
| franklin resources inc | 520,327 | $3.4M |
| vanguard capital management llc | 415,372 | $2.7M |
| blackrock, inc. | 213,388 | $1.4M |
| wellington management group llp | 194,108 | $1.3M |
| millennium management llc | 123,270 | $794K |
| two sigma investments, lp | 115,041 | $741K |
| geode capital management, llc | 101,695 | $655K |
| alyeska investment group, l.p. | 100,000 | $644K |
| renaissance technologies llc | 80,038 | $515K |
Showing top 10 of 35 institutional holders of Artiva Biotherapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 0.8
- Shares short
- 148,487
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARTV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Artiva Biotherapeutics, Inc.?
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell therapies, with its lead candidate AlloNK in clinical trials and other programs in preclinical stages.
Who is the CEO of Artiva Biotherapeutics, Inc.?
Dr. Fred Aslan M.D. is the chief executive officer of Artiva Biotherapeutics, Inc. (ARTV).
Where is Artiva Biotherapeutics, Inc. headquartered?
Artiva Biotherapeutics, Inc. (ARTV) is headquartered in San Diego, CA, United States.
What therapeutic areas does Artiva Biotherapeutics, Inc. focus on?
Artiva Biotherapeutics, Inc. develops therapies across Oncology, Gene Therapy, Immunology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.